Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Background Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised trial of the role of interleukin-1β inhibition in atherosclerosis, with the aim of establishing whether inhibition of a major product of the Nod-like receptor protein 3 (NLRP3) inflammasome with canakinumab might alter cancer incidence.Methods We did a randomised, double-blind, placebo-controlled trial of canakinumab in 10 061 patients with atherosclerosis who had had a myocardial infarction, were free of previously diagnosed cancer, and had concentrations of high-sensitivity C-reactive protein (hsCRP) of 2 mg/L or greater. To assess dose-response effects, patients were randomly assigned by computer-generated codes to three canakinumab doses (50 mg, 150 mg, and 300 mg, subcutaneously every 3 months) or placebo. Participants were followed up for incident cancer diagnoses, which were adjudicated by an oncology endpoint committee masked to drug or dose allocation. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, NCT01327846. The trial is closed (the last patient visit was in June, 2017).Findings Baseline concentrations of hsCRP (median 6·0 mg/L vs 4·2 mg/L; p<0·0001) and interleukin 6 (3·2 vs 2·6 ng/L; p<0·0001) were significantly higher among participants subsequently diagnosed with lung cancer than among those not diagnosed with cancer. During median follow-up of 3·7 years, compared with placebo, canakinumab was associated with dose-dependent reductions in concentrations of hsCRP of 26-41% and of interleukin 6 of 25-43% (p<0·0001 for all comparisons). Total cancer mortality (n=196) was significantly lower in the pooled canakinumab group than in the placebo group (p=0·0007 for trend across groups), but was significantly lower than placebo only in the 300 mg group individually (hazard ratio [HR] 0·49 [95% CI 0·31-0·75]; p=0·0009). Incident lung cancer (n=129) was significantly less frequent in the 150 mg (HR 0·61 [95% CI 0·39-0·97]; p=0·034) and 300 mg groups (HR 0·33 [95% CI 0·18-0·59]; p<0·0001; p<0·0001 for trend across groups). Lung cancer mortality was significantly less common in the canakinumab 300 mg group than in the placebo group (HR 0·23 [95% CI 0·10-0·54]; p=0·0002) and in the pooled canakinumab population than in the placebo group (p=0·0002 for trend across groups). Fatal infections or sepsis were significantly more common in the canakinumab groups than in the placebo group. All-cause mortality did not differ significantly between the canakinumab and placebo groups (HR 0·94 [95% CI 0·83-1·06]; p=0·31).Interpretation Our hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality. Replication of these data in formal settings of cancer screening and treatment is required.Funding Novartis Pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Thus, clinical studies have unraveled the capacity of IL-1b blockade to prevent the development of non-small-cell lung cancer in the elderly.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [86]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a recent human clinical study reported IL-1β inhibition with the neutralizing antibody canakinumab significantly reduced lung cancer incidence and mortality in a cohort of high-risk individuals (Ridker et al., 2017).”
From Commensal Microbiota Promote Lung Cancer Development via γδ T Cells (2019) · cites this paper as Ridker et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beyond meeting the primary endpoint of the trial, canakinumab reduced the incidence of diabetes and hypertension, as well as the incidence of, and mortality from, lung cancer 272 .”
From Hallmarks of aging: An expanding universe (2023) · cites this paper as [272]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“| | Human | Treatment of patients with a history of myocardial infarction and high hsCRP with canakinumab (Phase 3 trial) | Reduced incidence of hypertension and diabetes; reduced frequency of recurrent myocardial infarction and non-small cell lung cancer | 272 |”
From Hallmarks of aging: An expanding universe (2023) · cites this paper as [272]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“reducing the inflammatory markers, CRP and IL-6 (and likely other pro-inflammatory proteins) with canakinumab (a monoclonal antibody against IL-1β) dramatically reduced the incidence of lung cancer in these patients17.”
From The effect of smoking on chronic inflammation, immune function and blood cell composition (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationInflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Self-citation(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
Cited by
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationHallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Self-citation
Metadata
- Authors
- Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., Siostrzonek, P., Sinnaeve, P., Fonseca, F., Nicolau, J., Gotcheva, N., Genest, J., Yong, H., Urina-Triana, M., Milicic, D., Cifkova, R., Vettus, R., Koenig, W., Anker, S. D., Manolis, A. J., Wyss, F., Forster, T., Sigurdsson, A., Pais, P., Fucili, A., Ogawa, H., Shimokawa, H., Veze, I., Petrauskiene, B., Salvador, L., Kastelein, J., Cornel, J. H., Klemsdal, T. O., Medina, F., Budaj, A., Vida-Simiti, L., Kobalava, Z., Otasevic, P., Pella, D., Lainscak, M., Seung, K.-B., Commerford, P., Dellborg, M., Donath, M., Hwang, J.-J., Kultursay, H., Flather, M., Ballantyne, C., Bilazarian, S., Chang, W., East, C., Everett, B., Forgosh, L., Glynn, R., Harris, B., Libby, P., Ligueros, M., Thuren, T., Bohula, E., Charmarthi, B., Cheng, S., Chou, S., Danik, J., McMahon, G., Maron, B., Ning, M., Olenchock, B., Pande, R., Perlstein, T., Pradhan, A., Rost, N., Singhal, A., Taqueti, V., Wei, N., Burris, H., Cioffi, A., Dalseg, A. M., Ghosh, N., Gralow, J., Mayer, T., Rugo, H., Fowler, V., Limaye, A. P., Cosgrove, S., Levine, D., Lopes, R., Scott, J., Thuren, T., Ligueros, M., Hilkert, R., Tamesby, G., Mickel, C., Manning, B., Woelcke, J., Tan, M., Manfreda, S., Ponce, T., Kam, J., Saini, R., Banker, K., Salko, T., Nandy, P., Tawfik, R., O'Neil, G., Manne, S., Jirvankar, P., Lal, S., Nema, D., Jose, J., Collins, R., Bailey, K., Blumenthal, R., Colhoun, H., Gersh, B., & Glynn, R. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Novartis (Switzerland) (CH)
- ORCID
- Lorenzatti, Alberto
- Siostrzonek, Peter
- Sinnaeve, Peter
- Fonseca, Francisco
- Gotcheva, Nina
- Genest, Jacques
- Manolis, Athanasios J
- Fucili, Alessandro
- Ogawa, Hisao
- Shimokawa, Hiroaki
- Kastelein, John
- Cornel, Jan Hein
- Klemsdal, Tor Ole
- Budaj, Andrzej
- Kobalava, Zhanna
- Pella, Daniel
- Seung, Ki-Bae
- Donath, Marc
- Hwang, Juey-Jen
- Flather, Marcus
- Ballantyne, Christie
- Bohula, Erin
- Cheng, Susan
- Chou, Sherry
- Maron, Bradley
- Ning, MingMing
- Olenchock, Benjamin
- Pande, Reena
- Pradhan, Aruna
- Rost, Natalia
- Singhal, Aneesh
- Taqueti, Viviany
- Wei, Nancy
- Burris, Howard
- Cioffi, Angela
- Ghosh, Nilanjan
- Gralow, Julie
- Mayer, Tina
- Rugo, Hope
- Fowler, Vance
- Limaye, Ajit P
- Cosgrove, Sara
- Levine, Donald
- Hilkert, Robert
- Tan, Monique
- Jose, Jaison
- Collins, Rory
- Blumenthal, Roger
- Colhoun, Helen
- Gersh, Bernard
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 390
- Issue
- 10105
- Pages
- 1833-1842
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2750254726
- Cited by
- 1,344
- References
- 34
- Citations by year
- 2026: 132 · 2025: 127 · 2024: 164 · 2023: 147 · 2022: 142 · 2021: 140 · 2020: 164 · 2019: 155 · 2018: 142 · 2017: 30
- FWCI
- 54.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Funders
- Wellcome Trust (206632/Z/17/Z)
- National Institute of Neurological Disorders and Stroke (K23NS073806)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- canakinumab, IL-1β inhibition, lung cancer incidence, atherosclerosis, NLRP3 inflammasome, inflammation and cancer, high-sensitivity C-reactive protein, interleukin-6, cancer mortality, myocardial infarction, CANTOS trial, tumor microenvironment, dose-response relationship
- MeSH terms
- Aged, Anti-Inflammatory Agents, Antibodies, Monoclonal, C-Reactive Protein, Cell Transformation, Neoplastic, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Myocardial Infarction, Neutropenia, Smoking, Thrombocytopenia, Interleukin-6, Incidence, Sepsis, Atherosclerosis, Interleukin-1beta, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)32247-x
- The paper
- Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., Siostrzonek, P., Sinnaeve, P., Fonseca, F., Nicolau, J., Gotcheva, N., Genest, J., Yong, H., Urina-Triana, M., Milicic, D., . . . Glynn, R. J. (2017). Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)32247-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.